Evidence map›Paper›PMID 37409095›Full record

ArticleProstate international2023

A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways.

Yunlim Kim, Sangjun Yoo, Bumjin Lim, Jun Hyuk Hong, Cheol Kwak, Dalsan You, Jung Jin Hwang, Choung-Soo Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yunlim KimAsan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.
Sangjun YooDepartment of Urology, Seoul National University, Boramae Medical Center, Seoul, Korea.
Bumjin LimDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Jun Hyuk HongDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Cheol KwakDepartment of Urology, Seoul National University Hospital, Seoul, Korea.
Dalsan YouDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Jung Jin HwangAsan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.
Choung-Soo KimDepartment of Urology, Ewha Womans University Mokdong Hospital, Seoul, Korea.
Ulsan College · KREwha Womans University · KRAsan Medical Center · KRSeoul National University · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metformin and phenformin, biguanide derivatives that are widely used to treat type 2 diabetes mellitus, have recently been shown to exert potential anticancer effects in prostate cancer. This study compared the antiprostate cancer effects of the novel biguanide derivative IM176 with those of metformin and phenformin. Methods: Prostate cancer cell lines and patient-derived castration-resistant prostate cancer (CRPC) cells were treated with IMI76, metformin, and phenformin. The effects of these agents on cell viability, annexin V-FITC apoptosis, mammalian target of rapamycin inhibition, protein expression and phosphorylation, and gene expression were evaluated. Results: IM176 dose dependently reduced the viability of all prostate cancer cell lines tested, with IC Conclusion: The antitumor effects of IM176 were comparable with those of other biguanides. IM176 may therefore be a novel candidate for the treatment of patients with prostate cancer, including those with CRPC.

Indexed as

Androgen receptor splice variantBiguanideCastration-resistant prostate cancerCell death

Identifiers

PMID37409095
PMCPMC10318334
OpenAlexW4309476573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.